Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis
|
|
- Sybil Harrison
- 6 years ago
- Views:
Transcription
1 Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis Mercedes Iñarrairaegui, MD, PhD, Kenneth G. Thurston, MA, Jose I. Bilbao, MD, PhD, Delia D Avola, MD, Macarena Rodriguez, MD, Javier Arbizu, MD, PhD, Antonio Martinez-Cuesta, MD, MSc, FRCR, and Bruno Sangro, MD, PhD PURPOSE: Intraarterial delivery of yttrium-90 ( 90 Y) bound microspheres (ie, radioembolization) is a promising treatment for hepatocellular carcinoma (HCC). An early concern was the embolic nature of the microspheres, and their potential to reduce hepatic arterial blood flow in patients with compromised portal blood flow secondary to portal vein thrombosis/occlusion (PVT). In this situation, the risk of liver failure could be enhanced, particularly in patients with cirrhosis who have increased hepatic arterial blood flow. This retrospective analysis was undertaken to assess the safety and clinical benefits of radioembolization with 90 Y resin microspheres in HCC with branch or main PVT. MATERIALS AND METHODS: A total of 25 patients presenting with unresectable HCC and compromised portal flow received segmental, lobar, or whole-liver infusion of 90 Y resin microspheres. For the analysis of tumor response, changes in target lesions, appearance of new lesions, and changes in portal vein thrombus were studied. Controlled disease was defined by absence of progression in all these components. RESULTS: Globally, controlled disease was achieved in 66.7% of patients at 2 months and 50% of patients at 6 months. No significant changes were observed in liver-related toxicities according to Common Toxicity Criteria (version 3.0) at 1 and 2 months after treatment. Median survival time was 10 months (95% CI, months). CONCLUSIONS: Radioembolization of unresectable HCC and branch or main PVT with 90 Y resin microspheres was associated with minimal toxicity and a favorable median survival time. Further prospective studies are warranted to validate the findings in this clinically challenging patient population. J Vasc Interv Radiol 2010; 21: Abbreviations: HCC hepatocellular carcinoma, MAA macroaggregated albumin, PVT portal vein thrombosis/occlusion From the Liver Unit (M.I., D.D., B.S.) and Departments of Interventional Radiology (J.I.B., A.M.C.) and Nuclear Medicine (M.R., J.A.), Clinica Universitaria de Navarra, Pamplona;Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) (M.I., D.D., B.S.), Barcelona, Spain; and Sirtex Medical United States Holdings (K.G.T.), Wilmington, Massachusetts. Received September 22, 2009; final revision received February 22, 2010; accepted April 5, Address correspondence to B.S, Liver Unit, Clinica Universitaria de Navarra, Avda. Pio XII, Pamplona, Spain; bsangro@unav.es RADIOEMBOLIZATION with yttrium- 90 ( 90 Y) resin microspheres is an emerging treatment for unresectable liver disease in patients who are not amenable to Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) (M.I., D.D., B.S.) is funded by Instituto de Salud Carlos III. K.G.T. is a paid employee of Sirtex Medical United States Holdings (Wilmington, Massachusetts). None of the other authors have identified a conflict of interest. SIR, 2010 DOI: /j.jvir liver transplantation, resection, or selective ablative techniques (eg, radiofrequency ablation or percutaneous ethanol injection) (1,2). The microspheres loaded with 90 Y are delivered to liver tumors by means of endovascular catheters selectively placed within the hepatic arterial vasculature. The microspheres lodge preferentially within the neovessels of the tumor(s) and deliver high-energy -radiation over a limited range (mean penetration of radiation into tissues is 2.4 mm), thereby minimizing radiation exposure to normal liver parenchyma. Patients suitable for radioembolization are those with good per- 1205
2 1206 Radioembolization with 90 Y Microspheres in HCC and PV Thrombosis August 2010 JVIR formance status (Eastern Cooperative Oncology Group score 0 2), adequate hepatic functional reserve (total bilirubin 2.0 mg/dl, albumin 3.0 mg/ dl, platelet count ) and acceptable renal function (creatinine 2.0 mg/dl) (3). With meticulous angiographic technique and conservative models for dose calculation, patients experience minimal side effects (mild abdominal pain, nausea, and fatigue are most common) and are typically discharged from the hospital within 24 hours of treatment. Liver damage is infrequent, and in the absence of cirrhosis, it seems to be associated with bilobar treatment of patients heavily pretreated with antineoplastic chemotherapy (4). Median survival of patients with hepatocellular carcinoma (HCC) who are treated with 90 Y microspheres varies widely (between 5 and 27 months) in phase II and retrospective studies, depending on performance status, degree of hepatic functional reserve, extent of disease involvement, and presence or absence of cirrhosis (3 11). When radioembolization with 90 Y microspheres was first introduced into the clinic for the treatment of unresectable HCC, there was some concern regarding the potential for liver failure in patients presenting with portal vein thrombosis/occlusion (PVT). Portal vein thrombus arises as a result of the vascular invasion of primary tumor or as a consequence of sluggish blood flow. A variable but significant proportion of patients with HCC (range, 15% 40%) present with PVT (12,13), and the actuarial probabilities of developing vascular invasion at 1, 2, and 3 years are 21%, 29%, and 46%, respectively, in patients with cirrhosis and unresectable HCC (12). These patients have a poor prognosis (14), and locoregional therapies including transarterial chemoembolization or bland embolization are usually contraindicated (15). In radioembolization treatment, although most microspheres are ultimately embedded in the small vessels of the periphery of tumor nodules, aggregation and occlusion of medium-sized vessels can also occur, resulting in reduced arterial blood flow (16). Therefore, although the principal mode of action for radioactive microspheres relies on irradiation, a combined radioembolic effect cannot be ruled out. Medium-sized vessel occlusion can also occur in the nontumoral liver parenchyma regardless of the presence of cirrhosis (4). Hence, in patients presenting with PVT, there is a concern of an increased risk of liver failure as a result of the preexistent reduction of portal flow and the incremental compromise of arterial hepatic perfusion caused by the embolization of microspheres in the hepatic micro- and macrovessels. As a result, 90 Y microsphere therapy has historically been contraindicated in patients presenting with PVT (17,18). Recent studies with 90 Y glass microspheres have suggested that the original safety concerns regarding risk of hepatic compromise in patients presenting with PVT may have been unfounded (19). An intense embolizing effect of glass microspheres has been recently ruled out by analyzing the pattern of arterial blood flow after contrast agent power injection immediately after treatment (20). In addition, a phase II study in 37 patients with HCC presenting with PVT (21) showed a favorable toxicity profile after radioembolization with 90 Y glass microspheres. Based on the lower radiation activity per microsphere, a greater number of resin microspheres are needed for a standard treatment, and this may translate into a more intense embolizing effect, although this issue has not been previously analyzed to our knowledge. In animal models, 90 Y-free resin microspheres do not cause significant acute ischemia and the microspheres are usually incorporated into the vessel wall or excluded from the circulation after 2 months (22). However, evidence from the clinical setting is lacking. The current retrospective analysis was conducted to assess the safety regarding a hypothetical embolizing effect and potential clinical benefit of 90 Y resin microspheres (SIR-Spheres; Sirtex Medical, Bonn, Germany) in the treatment of patients with unresectable HCC who present with PVT. MATERIALS AND METHODS Patient Cohort Twenty-five patients with unresectable HCC presenting with branch or main PVT were treated between September 2003 and September 2009 at a single institution. Beginning in September 2003, all consecutive patients with HCC who were ineligible for radical treatments (surgery, liver transplantation, or percutaneous ablation) or chemoembolization as a result of the presence of PVT or extensive tumor burden were evaluated for radioembolization. Eligibility criteria for this study included (i) age of at least 18 years; (ii) preserved liver function with a Child- Pugh score no greater than 7 and no ascites; (iii) platelet count greater than ; (iv) no contraindication to angiography; and (v) signed informed consent. Thirty-two patients presented with branch or main PVT, seven of whom were not treated for the following reasons: intense mismatch between intrahepatic technetium Tc 99m macroaggregated albumin (MAA) distribution and liver lesions (local exclusion criterion; n 3), high lung shunting (n 2), massive intratumoral arterioportal shunt (n 1), and clinical deterioration before treatment (n 1). Treatment Protocol The protocol for 90 Y resin microsphere therapy is provided elsewhere (23). In summary, patients underwent a planning angiographic study to (i) identify vascular anatomy, HCC feeding vessels, aberrant vessels and extrahepatic collateral vessels feeding extrahepatic organs (especially the gastrointestinal tract), and the presence of intrahepatic or intratumoral arterioportal shunting; and (ii) evaluate the direction of portal blood flow (hepatopetal or hepatofugal) and, in case of PVT, the presence of bypassing blood flow through collateral vessels). Aberrant hepatic vessels and extrahepatic collaterals were coil-embolized to prevent the inadvertent misplacement of 90 Y resin microspheres into the gastrointestinal tract or pancreas. Technetium Tc 99m labeled MAA particles were then injected with the delivery catheter in the intended position for 90 Y resin microsphere infusion. All the patients underwent 99m Tc-MAA planar imaging and single photon emission computed tomography (CT) to assess pulmonary shunt and any unintended flow to other extrahepatic organs. Any patient who exhibited an intense mismatch between intrahepatic 99m Tc-MAA distribution and liver lesions as viewed on fusion imaging with single photon emission CT and CT or magnetic resonance (MR) imaging was ineligible for treatment. Dosimetry was calculated to maximize the therapeutic activity to tu-
3 Volume 21 Number 8 Iñarrairaegui et al 1207 morous tissue and minimize exposure of nontumoral parenchyma and lung tissue. Within 2 weeks of the planning angiography study, the prescribed activity of 90 Y resin microspheres was administered by placing the tip of the delivery catheter in the same anatomic position as that used for the 99m Tc-MAA injection. Treatment protocol was approved institutionally. Data Collection and Follow-up Ethics committee approval was obtained for data analysis. Medical records were reviewed, and the following data were collected at baseline: age, sex, presence of cirrhosis per histologic or clinical/imaging criteria, extent of portal vein occlusion (segmental, branch, or main) and liver disease involvement (left lobe, right lobe, both lobes), extent of hepatic involvement (number and size of nodules) via MR imaging or CT, laboratory parameters including complete blood cell count, liver function tests, serum creatinine, anti hepatitis C virus antibodies and hepatitis B surface antigen, Eastern Cooperative Oncology Group performance status, and Cancer of the Liver Italian Program score (24). To assess changes in liver function secondary to the embolizing effect of radioembolization, serum levels of bilirubin and prothrombin activity and the occurrence of ascites and hepatic encephalopathy were recorded at baseline and 1 and 2 months after treatment. The same parameters were also recorded at month 6 to evaluate long-term effects. Adverse events were classified and coded for severity according to Common Terminology Criteria for Adverse Events, version 3.0 (25). Tumor response following radioembolization was assessed at 2 and 6 months by MR imaging or CT scan. In the evaluation of tumor response, the parenchymal and intravascular components of disease were assessed. For the former, changes in size of target lesions were assessed according to Response Evaluation Criteria In Solid Tumors (26) in those patients with measurable disease, and the development of new lesions was assessed in all patients. For the latter, changes in the extent of PVT were evaluated and classified as partial response (ie, clearance or regression of tumor thrombus into a more distal portal vein segment), stable disease (ie, no changes), or progressive disease (ie, progression of tumor thrombus into a more proximal portal vein segment). Finally, a global response was established as progressive disease whenever a patient had tumor progression in any of the three individual parameters (measurable target lesions, new lesions, or tumor thrombus) and controlled disease in any other case. Survival was determined from the time of treatment until death. Patients lost to follow-up were censored at the date of their last known visit. Statistical Analysis Descriptive statistics for nominal, ordinal, and continuous variables, including frequency, median, and average, were used as appropriate. Proportions of patients with liver toxicities before and after treatment were compared by using the McNemar test. Survival from date of treatment was calculated with the Kaplan-Meier method. A P value lower than.05 was considered statistically significant. A commercial statistical software package (SPSS version ; SPSS, Chicago, Illinois) was used for data analysis. RESULTS Patient Characteristics and Treatment Table 1 presents the baseline characteristics of the 25 patients (median age, 66 years) with PVT who received 90 Y resin microsphere treatment. Median follow-up was 8 months (interquartile range, months), and only one patient was lost to follow-up 7 months after treatment. Most patients were men (88%) and presented with cirrhosis (92%) and bilobar disease (56%). Vessel occlusion was identified in the main portal vein in 24% of patients and in the right or left branches in 64% of patients. Two patients presented with segmental portal vein occlusion. In five patients, collateral vessels were embolized during the arteriographic evaluation. Adequate liver reserve was reflected by median serum bilirubin level of 1.15 mg/dl (interquartile range, mg/dl) and absence of ascites. All patients had Barcelona Clinic Liver Cancer stage C disease. Patients presented with a high tumor burden (median tumor volume, 241 ml; interquartile range, ml; median tumor involvement, 13.6%; interquartile range, 7.9% 40.4%), and 44% of patients had more than five nodules. The treatment parameters for the patient cohort are outlined in Table 2. Yttrium-90 resin microspheres were injected into the right or the left hepatic artery in 16 patients (64%), the tumorfeeding vessel in three patients (12%), and the right hepatic and segment IV arteries in three patients (12%). Wholeliver treatment was performed in three patients (12%): one patient received 90 Y resin microsphere infusion from the common hepatic artery and the other two received sequential infusions into the right and left hepatic branches with a 3-week and 8-week interval, respectively. The median activity administered was 1.8 GBq (range, GBq). All patients successfully received the whole dose prescribed, without stasis during infusion. This wide range in administered activity relies on the different tumor burden treated in each patient. The average pulmonary shunt fraction was 9% and no patient received an excessive (ie, 30 Gy) radiation dose to the lung. Tumor Response The clinical outcomes for the patients treated are presented in Table 3. One patient died from adhesive large bowel obstruction before initial assessment. Seven of the remaining 24 patients had nonmeasurable parenchymal target disease (ie, diffuse or massive tumors) that could not be evaluated for response. Globally, progressive disease was observed at 2 months in eight patients (33.3%). Sites of progression included target lesions (in one patient who had an internal hemorrhage in one of the nodules that was responsible for the increased size), new lesions (n 6), and tumor thrombus (n 1). Controlled disease was observed in 16 patients (66.7%), including a partial response of the target lesion in one patient. Among the 16 patients who reached 6-month follow-up and were evaluable for response, eight (50%) had progressive disease. Sites of progression included new lesions (n 7) and tumor thrombus (n 1). Controlled disease was observed in eight patients (50%), including a partial response of the target lesions in two patients. Among the 19 patients with branch and segmental PVT, one patient showed a complete resolution of portal vein in-
4 1208 Radioembolization with 90 Y Microspheres in HCC and PV Thrombosis August 2010 JVIR Table 1 Baseline Characteristics of Study Patients (N 25) Characteristic Value Median (range) age (y) 66 (46 75) Male sex 22 (88) Portal vein occlusion Right PVT 10 Left PVT 6 Segmental PVT 2 Right and left PVT 1 Main PVT 2 Main and right PVT 2 Main, right, and left PVT 2 CLIP tumor stage 1 3 (12) 2 10 (40) 3 10 (40) 4 2 (8) Cirrhosis 23 (92) No. of nodules (56) 5 11 (44) Median (range) tumor volume (ml) 241 (18 2,000) Median (range) tumor involvement* 13.6 ( ) Median (range) total bilirubin (mg/dl) 1.15 ( ) Note. Values in parentheses are percentages unless specified otherwise. CLIP Cancer of the Liver Italian Program. * Calculated as tumor volume divided by total liver volume. Table 2 Characteristics of Treatment Characteristic Value Extent of treatment* Selective 3 (12) Lobar 16 (64) Extended lobar 3 (12) Whole liver 3 (12) Median (range) activity administered (GBq) 1.8 ( ) Median (range) pulmonary shunt fraction (%) 9 (2 32.4) Note. Values in parentheses are percentages unless specified otherwise. * Selective treatment involved infusion of microspheres via the feeding vessel to the tumor; lobar treatment included infusion to a single lobe via the right or left hepatic arteries; extended lobar included infusion from the right hepatic and segment IV arteries; whole-liver treatment was accomplished via (i) infusion of microspheres through the proper hepatic artery or (ii) double infusion via the right and left branches beyond the proper hepatic artery. vasion 4 months after treatment, 13 had not shown a progression to complete PVT after a median of 8 months (range, 1 26 months), two patients showed progression to complete PVT 8 months and 3 years after treatment, respectively, and one patient with left PVT showed progression to segmental right PVT 2 months after treatment. Additionally, two patients with right PVT developed new lesions with vascular invasion in the left lobe 2 and 17 months after treatment, respectively. Side Effects and Long-term Outcome Although some patients experienced mild pain during the infusion of 90 Y resin microspheres, there was no evidence of postembolization syndrome. There was also no evidence of altered liver function as a result of sustained reduction in vascular supply to nontumorous liver or acute ischemic hepatitis caused by severe, immediate reduction in vascular supply. As shown in Table 4, relevant changes in liver function were not observed in the first 2 months after radioembolization. One patient developed hepatic encephalopathy because of an adhesive large bowel obstruction that will be explained later in detail, two patients developed ascites 2 months after treatment, and no differences were observed in prothrombin activity. Regarding total bilirubin, although no differences were observed in the proportion of patients with abnormal levels according to Common Toxicity Criteria, a statistically significant but clinically irrelevant increase was observed after radioembolization. Median values were 1.15 mg/dl at baseline, 1.21 mg/dl at 1 month (P.01 vs baseline), and 1.4 mg/dl at 2 months (P.007 vs. baseline). Six months after treatment, when tumors had already progressed in some patients, median bilirubin level was 1.32 mg/dl, four patients developed grade 2 and 3 ascites, and two patients developed grade 3 encephalopathy. As illustrated in the Figure, median overall survival time was 10 months (95% CI, months). Eighteen patients died 2 44 months after radioembolization and, as of the time of manuscript preparation, seven patients are alive between 2 and 24 months after treatment. In 11 of the 18 patients who died, tumor progression was the suspected cause of death. In one of them, despite no major change in size, the tumor progressed toward the inferior cava vein and the patient developed ascites and renal failure. Among four patients with diffuse single-lobe tumors that were treated from the corresponding lobar artery, two died 8 months after treatment from tumor progression that was predominant in the contralateral lobe and two died 16 and 45 months after treatment, respectively, from hepatic and extrahepatic tumor progression after having received sorafenib, without response. PVT progressed in two of these four patients. Three patients with bilobar disease treated by whole-liver or extended lobar infusion died from tumor progression 14, 24, and 26 months after treatment, respectively. Three additional patients with bilobar involve-
5 Volume 21 Number 8 Iñarrairaegui et al 1209 Table 3 Treatment Outcomes Outcome 2 Months (n 24) 6 Months (n 16) Parenchymal component Target lesions* Controlled disease 16 (94) 9 (100) Progressive disease 1 (6) 0 New lesions 6 (24) 7 (43.7) Intravascular component Controlled disease 22 (91.6) 15 (93.7) Progressive disease 1 (4.1) 1 (6.3) Global response Controlled disease 16 (66.7) 8 (50) Progressive disease 8 (33.3) 8 (50) Note. Values in parentheses are percentages. RECIST Response Evaluation Criteria in Solid Tumors. Controlled disease means (i) partial response or stable disease according to RECIST for target measurable lesions in parenchymal component, (ii) absence of progression of tumor thrombus into a more proximal portal vein segment for intravascular component, and (iii) controlled disease in the parenchymal and intravascular components for global response. Progressive disease means absence of controlled disease. * Target lesions were evaluated according to RECIST only in patients with measurable disease (n 17 at month 2 and n 9 at month 6). Table 4 Liver-related Side Effects* Toxicity/CTC Grade Basal (N 25) Month 1 (N 25) Month 2 (n 24) Month 6 (n 16) Bilirubin Total 12 (48) 11 (51) 15 (64) 10 (61) 1 9 (36) 6 (28) 8 (34) 5 (31) 2 3 (12) 5 (23) 6 (26) 3 (18) (4) 2 (12) INR Total 1 (5) 1 (4) 1 (4) (5) 1 (4) 1 (4) Ascites Total (8) 4 (24) (8) 2 (12) (12) Encephalopathy Total 0 1 (4) 0 2 (12) (4) (12) Note. Values in parentheses are percentages. CTC Common Toxicity Criteria (version 3); INR International Normalized Ratio. * Differences between time points were not significant for any of the toxicities. Twenty-one patients were available for assessment of blood parameters at 1 month. Twenty-three patients were available for assessment of blood parameters at 2 months. ment that included massive lesions in one lobe and few lesions in the contralateral lobe were treated from the corresponding lobar artery. In all cases, the targeted disease remained stable but tumors progressed in the form of new lesions in the contralateral lobe (two patients also developed extrahepatic metastases) and patients died 6, 11, and 14 months after radioembolization. All six of these patients received sorafenib but showed no tumor response. In seven patients, the cause of death was not likely to be tumor progression. One patient developed an adhesive large bowel obstruction 10 days after treatment, underwent a subtotal colectomy that had a problematic course complicated with infection, cardiac arrhythmia, and hepatic encephalopathy, and finally died 2 months after treatment. A second patient developed obstructive jaundice after 3 months and died from variceal bleeding nearly 4 months after radioembolization. In a third patient who underwent selective treatment, the treated lesion remained stable but the patient developed biliary tract compression by hilar lymph node metastases and died of cholangitis in another hospital. A fourth patient treated from the right hepatic artery whose disease had been controlled despite a slightly increased bilirubin level of 3.2 mg/dl at 3 months died from an unknown cause at a different center 4 months after radioembolization. A fifth patient received treatment from the left artery and had stable disease as the better response in the treated area but showed disease progression in the right lobe and received a second radioembolization procedure 5 months later. By this second treatment, the patient s basal bilirubin level was 3.35 mg/dl, and 3 months later, worsening liver function and ascites were seen. The patient died 11 months after the first treatment (5 months after the second treatment). A sixth patient treated from a right segmental artery showed bilirubin levels increased to 3.17 mg/dl 2 months after radioembolization, and 1 month later the patient developed refractory ascites and died 8 months after treatment. The final patient in this group was treated from the right hepatic artery and the targeted lesion remained stable without progression, but 6 months after treatment, the patient developed ascites with worsening liver function and died 8 months after radioembolization. In the latter four patients, it was difficult to identify the likely cause of liver failure, but tumor progression was not considered a major contributor. Although cirrhosis itself is a progressive disease and decompensation is not uncommon,
6 1210 Radioembolization with 90 Y Microspheres in HCC and PV Thrombosis August 2010 JVIR Figure. Overall survival from the date of treatment with 90 Y radioembolization among 25 patients with HCC who presented with PVT. treatment-induced liver disease cannot be ruled out. At the time of evaluation, seven patients were alive and had good liver function. One patient with a large single tumor that replaced virtually the entire right lobe showed an intense response and received two additional radioembolization procedures 7 and 18 months after the first treatment. The patient continues to have a stable partial response 24 months after the first treatment. A second patient with a right-sided lesion treated from the right artery showed stable disease during 17 months, but then new lesions developed in the left lobe with thrombosis of the left hepatic artery, and the patient started sorafenib therapy. He was alive 19 months after treatment with preserved liver function. Another patient was lost to follow-up 7 months after radioembolization, and the last scan performed at 2 months showed progression of target lesions as a result of internal hemorrhage of one nodule. Another patient showed lung progression with stable disease in the liver 6 months after treatment. Three additional patients were alive and with good liver function 2 months after treatment (two with stable disease and one with a new portal invading lesion in the contralateral lobe). DISCUSSION The introduction of radioembolization for the treatment of patients with HCC and PVT has been tempered by concerns regarding the potential increased risk of liver failure, complications, and death as a result of impairment of hepatic vascular supply in the presence of compromised portal blood flow (18,19). These concerns have been driven by the previous experience with intense embolic therapies such as chemoembolization. Randomized studies involving chemoembolization have typically excluded patients with vascular invasion, including segmental portal obstruction, in view of the increased risk of compromised hepatic arterial flow (27). A randomized study of chemoembolization versus untreated controls found the relative risk of death for patients with unilobar (ie, branch) portal vein obstruction treated with chemoembolization was 2.71 (P.004) compared with patients without PVT (28). By contrast, the current study suggests that 90 Y resin microspheres may be used with a decreased risk of complication and may provide some clinical benefit in this challenging patient population. If there were an incremental effect of significant impairment of hepatic arterial blood flow in concert with preexisting portal flow compromise, one would expect three possible scenarios after radioembolization: (i) postembolization syndrome resulting from tumor ischemia; (ii) altered liver function resulting from minor but sustained reduction in vascular supply to nontumorous tissue; or (iii) acute ischemic hepatitis resulting from severe, immediate reduction in vascular supply. None of these clinical phenomena have been observed in these patients with PVT who were treated with 90 Y resin microspheres, although the slight increase in serum bilirubin may reflect a subclinical embolic effect. In 2004, Salem and colleagues (19) reported clinical outcomes after treatment with glass 90 Y microspheres in 15 patients with HCC presenting with branch PVT. Other than increased posttreatment bilirubin level in five patients (four of whom had evidence of intrahepatic disease progression), there were no significant clinical sequelae from treatment. A second phase II study (20) showed that patients with branch PVT (n 25) exhibited a similar incidence of increased bilirubin compared with those without PVT (n 71; 42% vs 35%, respectively). For patients presenting with main PVT, the incidence of increased bilirubin level was 64% higher after radioembolization; although this was not statistically significant (P.20) (20). Increased bilirubin level has been shown to be a good indicator of overall hepatic function. Nevertheless, our study showed only a mild increase at 1 and 2 months after treatment, which would suggest an absence of clinically relevant ischemia-induced effect. Indeed, this same phenomenon is observed in patients with PVT who are treated with 90 Y microspheres and could reflect a subtle effect of radiation. A study of treatment with 90 Y glass microspheres in 37 patients with PVT (21) indicated a posttreatment increase in bilirubin level (Southwest Oncology Group grade 3 5) in 32% of branch PVT cases (n 25) and 58% of main PVT cases (n 12). Clinically detectable posttreatment ascites (Southwest Oncology Group grade 2 4) was evident in 8% of branch PVT cases and 50% of main PVT cases. The authors attributed the higher incidence of liver-related events in the main PVT group to their more advanced disease stage and worsened prognosis (21). In the current study, controlled disease was observed in the majority of patients (66.7%) at 2 months and in 50% at 6 months. Notably, although main PVT usually leads to an increased risk of liver decompensation and ascites, only
7 Volume 21 Number 8 Iñarrairaegui et al 1211 two cases of branch PVT evolved to main PVT. The median survival time in the current study cohort was 10.0 months, which compares favorably with the median survival of 10.1 months for patients with branch PVT who are treated with glass microspheres, and exceeds the 4.5- month median survival time of patients with main PVT (21). The results of this study compare favorably with the median survival time of 2.7 months in untreated patients with HCC and PVT (14) and the survival times of 8.9 and 6.7 months in patients with PVT or extrahepatic disease and Child-Pugh class A disease treated with sorafenib or placebo, respectively, in a recent controlled study (29). One of the major drawbacks of the present study is its retrospective design. After 90 Y radioembolization, all patients did not have imaging procedures done at the same intervals, so time to progression could not be calculated. Systemic therapy with sorafenib was not started at the same time after 90 Y treatment in all patients who showed progressive disease, and this may have influenced overall survival. Finally, the small number of patients, especially in the main PVT group (n 6), did not allow the calculation of differences in survival between branch and main PVT cases. Based on the results of the present study, it appears that radioembolization with 90 Y resin microspheres offers a favorable risk/benefit profile for patients presenting with unresectable HCC and branch or main PVT. Unlike other embolic therapies such as chemoembolization, radioembolization appears to be an effective treatment for patients who otherwise have limited treatment options and present with a poor prognosis. Further prospective clinical studies are required to validate the findings from our small patient sample and to evaluate radioembolization with and without sorafenib compared with sorafenib alone. Acknowledgments: The authors acknowledge the contribution of Carmen Fuertes to the conduct of this study. References 1. Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodological considerations. J Vasc Interv Radiol 2006; 17: Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol 2006; 17: Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium (REBOC). Int J Radiat Oncol Biol Phys 2007; 68: Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112: Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y microspheres. J Nucl Med 2000; 41: Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127 (Suppl):S194 S Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 2005; 16: Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres: safety, tumor response and survival. J Vasc Interv Radiol 2005; 16: Lau WY, Ho S, Leung TWT, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intrarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998; 40: Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: Iñarrairaegui M, Martinez-Cuesta A, Rodríguez M, et al. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010 (in press); /j.ijrobp Trevisani F, D Intino PE, Caraceni P, et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer 1995; 7: Calvet X, Bruix J, Ginés P, et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology 1990; 12: Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Phys 2004; 60: Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 2: special topics. J Vasc Interv Radiol 2006; 17: Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68: Salem R, Lewandowski R, Roberts C, et al. Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004; 15: Sato K, Lewandowski RJ, Bui JT, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006; 29: Kulik L, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: Bilbao J, De Martino A, De Luis E, et al. Biocompatibility, inflammatory response and recanalization characteristics of non-radioactive resin microspheres: histological findings. Cardiovasc Intervent Radiol 2009; 32: Sangro B, Bilbao JI, Boan J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int
8 1212 Radioembolization with 90 Y Microspheres in HCC and PV Thrombosis August 2010 JVIR J Radiat Oncol Biol Phys 2006; 66: Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Hepatology 2001; 34: Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 3.0, March 31, Bethesda, MD: National Institutes of Health, Therasse P, Arbuck SG, Eisenhauer EA, et al. Special article: new guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: Llovet JM, Real MI, Montaña X, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable carcinoma: a randomized controlled trial. Lancet 2002; 359: Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: Sherman M, Mazzaferro V, Amadori D, et al, on behalf of the SHARP investigators study group. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: a subanalysis from the SHARP trial (abstr.). J Clin Oncol 2008; 26 (Suppl):4584.
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1674-1679 Radioembolization in Treatment of Hepatocellular Carcinoma with Portal Vein Invasion Elsahhar Ahmed Hetta, Osama Mohamed
More information100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days
100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,
More informationSelection Criteria and Insertion of SIRT into HCC Treatment Guidelines
Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationMinimizing Unnecessary Radiation Exposure to Healthcare Professionals and Patients Imagine where we can go.
ALARA & RADIATION SAFETY Minimizing Unnecessary Radiation Exposure to Healthcare Professionals and Patients Imagine where we can go. What is ALARA? As Low As Reasonably Achievable The use of radiation
More informationSIRT for Intermediate and Advanced HCC
Pamplona, junio de 2008 SIRT for Intermediate and Advanced HCC Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain 90 Y-RE MRI SPECT FUSION 90 Y-RE = Yttrium-90 radioembolization Sangro
More informationRadioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases
Radioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases Pr Francesco Giammarile CHLS Lyon Faculté de Lyon Sud «Aut tace aut loquere meliora silentio» Malignant
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of selective internal radiation therapy for primary liver cancer Selective internal
More informationMULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC
Dr Apoorva Gogna MBBS FRCR FAMS Consultant Interventional Radiology Center Department of Diagnostic Radiology SingaporeGeneral Hospital MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC CASE HISTORY
More informationStaging & Current treatment of HCC
Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt
More informationTrans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis?
Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Poster No.: C-1634 Congress: ECR 2014 Type: Authors: Keywords: DOI:
More informationALARA and Radiation Safety
ALARA and Radiation Safety Experience the power of TheraSphere and deliver hope where it s needed most. Imagine where we can go. btg-im.com What is TheraSphere? TheraSphere is indicated for radiation treatment
More informationRadioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma
Original Article Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma Munveer Singh Bhangoo 1, Diraj R. Karnani 1, Paul N. Hein 2, Huan Giap 3, Harry Knowles
More informationYTTRIUM-90 MICROSPHERES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A REVIEW
doi:10.1016/j.ijrobp.2006.02.061 Int. J. Radiation Oncology Biol. Phys., Vol. 66, No. 2, Supplement, pp. S83 S88, 2006 Copyright 2006 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/06/$
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationSIRT Dosimetry: Sometimes Less Is More
SIRT Dosimetry: Sometimes Less Is More Navesh K. Sharma, DO, PhD Assistant Professor, Departments of Radiation Oncology, Diagnostic Radiology and Nuclear Medicine Medical Director, Radiation Oncology,
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationLocoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates
Locoregional Treatments for HCC Applications in Transplant Candidates Matthew Casey, MD March 31, 2016 Locoregional Treatments for HCC Applications in Transplant Candidates *No disclosures *Off-label uses
More informationHepatocellular carcinoma (HCC) is the most common
Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes RIAD SALEM,*,, ROBERT J. LEWANDOWSKI,* MARY F. MULCAHY, AHSUN RIAZ,* ROBERT K.
More informationSELECTIVE INTERNAL RADIATION THERAPY FOR TREATMENT OF LIVER CANCER
SELECTIVE INTERNAL RADIATION THERAPY FOR TREATMENT OF LIVER CANCER SIR-Spheres*: A New Treatment Option for Non-Resectable Liver Tumors Treatment Overview SIRT: Selective Internal Radiation Therapy Concept
More informationHCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation
HCC Imaging and Advances in Locoregional Therapy David S. Kirsch MD Ochsner Clinic Foundation -Nothing to disclose Hepatic Imaging Primary imaging modalities include: US CT MR Angiography Nuclear medicine
More informationRadioembolization for hepatocellular carcinoma
Review Radioembolization for hepatocellular carcinoma Bruno Sangro 1,3,, Mercedes Iñarrairaegui 1,3, Jose I. Bilbao 2 1 Liver Unit, Clinica Universidad de Navarra, Pamplona, Spain; 2 Interventional Radiology,
More informationShe, WH; Cheung, TT; Yau, TCC; Chan, ACY; Chok, KSH; Chu, SKF; Liu, KY; Poon, RTP; Chan, SC; Fan, ST; Lo, CM
Title Survival analysis of transarterial radioembolization with yttrium- 90 for hepatocellular carcinoma patients with HBV infection Author(s) She, WH; Cheung, TT; Yau, TCC; Chan, ACY; Chok, KSH; Chu,
More informationMinimizing Unnecessary Radiation Exposure to Healthcare Professionals and Patients Imagine where we can go.
ALARA & RADIATION SAFETY Minimizing Unnecessary Radiation Exposure to Healthcare Professionals and Patients Imagine where we can go. What is ALARA? As Low As Reasonably Achievable The use of radiation
More informationInterventional Radiologic Treatment of Hepatocellular Carcinoma
Interventional Radiologic Treatment of Hepatocellular Carcinoma Fatih Boyvat Abstract The current treatment modalities for patients with hepatocellular carcinoma are discussed in this review. Hepatocellular
More informationGastroduodenal injury after radioembolization of hepatic tumors
Gastroduodenal injury after radioembolization of hepatic tumors Cristina Carretero, M.D., 1 Miguel Munoz-Navas, M.D., Ph.D., 1 Maite Betes, M.D., Ph.D., 1 Ramon Angos, M.D., Ph.D., 1 Jose C. Subtil, M.D.,
More informationHepatocellular Carcinoma (HCC)
Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationSelective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study
Original Article Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study Parvez S. Mantry 1, Ashwini Mehta
More informationHCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros)
HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros) Yi-Hsiang Huang, MD, Ph.D. Professor, Division of Gastroenterology & Hepatology,
More informationGuidelines for SIRT in HCC An Evolution
Guidelines for SIRT in HCC An Evolution 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore The challenge of HCC Surgery is potentially curative in early
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationIntra-arterial Therapy in Management of HCC: ctace, DEB-TACE, and Y90 Radioembolization
Intra-arterial Therapy in Management of HCC: ctace, DEB-TACE, and Y90 Radioembolization Department of Radiology, National Cancer Center In Joon Lee Contents Conventional TACE Role of TACE in management
More informationin Hepatocellular Carcinoma
in Hepatocellular Carcinoma The following summarises the key data supporting the use of SIR-Spheres Y-90 resin microspheres in the treatment of primary liver cancer due to hepatocellular carcinoma (HCC):
More informationHepatocellular carcinoma: Intra-arterial treatments
Hepatocellular carcinoma: Intra-arterial treatments Irene Bargellini U.O. Radiologia Interventistica Azienda Ospedaliero Universitaria Pisana IRENE BARGELLINI,MD UO RADIOLOGIA INTERVENTISTICA, AZIENDA
More informationY90 SIRT Therapy Dosimetric Aspects
Y90 SIRT Therapy Dosimetric Aspects David Chee-Eng Ng MBBS, BSc, MSc, MRCP, FAMS, FRCP (Edin) Head and Senior Consultant, Department of Nuclear Medicine and PET Singapore General Hospital Adjunct Assistant
More informationTRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD
UNIVERSITY OF PRETORIA STEVE BIKO ACADEMIC HOSPITAL SOUTH AFRICA TRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD 1 INTRODUCTION Hepatic
More informationRadioembolization of the Liver. Michael Meuse, M.D. Vascular and Interventional Radiology
Radioembolization of the Liver Michael Meuse, M.D. Vascular and Interventional Radiology Brachytherapy Principle Radiation is accepted as a standard treatment option for liver cancer Radiation will break
More informationInterventional Radiology in Liver Cancer. Nakarin Inmutto MD
Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT
More informationClinical Study Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience
International Journal of Surgical Oncology Volume 20, Article ID 5726, 9 pages doi:0.55/20/5726 Clinical Study Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution
More informationLocoregional Therapy for Hepatoma
Locoregional Therapy for Hepatoma Robert D. Crane, MD Interventional Radiology Virginia Mason How do we know a liver mass is HCC? HCC : Bx Of pts getting liver transplant only ~ 5% had Bx to establish
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationTreatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center
Treatment of Hepatocellular Carcinoma Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Epidemiology of HCC: world The 5 th most common cancer worldwide > 500, 000 new
More informationRuolo della interventistica per le secondarietà epatiche e di altre sedi
Ruolo della interventistica per le secondarietà epatiche e di altre sedi Giancarlo Bizzarri Dipartimento di Diagnostica per Immagini e Radiologia Interventistica Ospedale Regina Apostolorum, Albano Laziale
More informationConformal external beam radiation or selective internal radiation therapy a comparison of treatment outcomes for hepatocellular carcinoma
Original Article Conformal external beam radiation or selective internal radiation therapy a comparison of treatment outcomes for hepatocellular carcinoma Oluwadamilola T. Oladeru 1, Joseph A. Miccio 1,
More informationPRIOR AUTHORIZATION Prior authorization is required for BlueCHiP for Medicare members and recommended for Commercial products.
Medical Coverage Policy Radioembolization for Primary and Metastatic Tumors of the Liver EFFECTIVE DATE: 10 06 2009 POLICY LAST UPDATED: 08 02 2016 OVERVIEW Radioembolization (RE), referred to as selective
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationHepatocellular carcinoma (HCC) is a global
Radioembolization with Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma: European Experience on Safety and Long-Term Survival Philip Hilgard, 1 Monia Hamami, 2 Amr El Fouly, 1 André Scherag, 3
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationDisclosures. I am on the Onyx speaker bureau I am a paid consultant to. Boston Scientific CeloNova Cook MDS Nordion Sirtex
Disclosures I am on the Onyx speaker bureau I am a paid consultant to Boston Scientific CeloNova Cook MDS Nordion Sirtex Comparing Y90 Devices Matthew S. Johnson MD, FSIR Indiana University School of Medicine
More informationVolume 20 Number 5 Siddiqi and Devlin 665 Figure 1. Axial CT image in portal venous phase before treatment with 90 Y spheres. Low-density areas, some
Radiation Lobectomy A Minimally Invasive Treatment Model for Liver Cancer: Case Report Nasir H. Siddiqi, MD, Phillip M. Devlin, MD Chemotherapy-resistant colon carcinoma metastases to a patient s right
More informationRadioembolization: technical aspects
Radioembolization: technical aspects Rita Golfieri Unità Operativa Radiologia Malpighi Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola - Malpighi La sottoscritta dichiara di non aver
More informationHepatocellular carcinoma (HCC) is one of the
Survival After Yttrium-90 Resin Microsphere Radioembolization of Hepatocellular Carcinoma Across Barcelona Clinic Liver Cancer Stages: A European Evaluation Bruno Sangro, 1 Livio Carpanese, 2 Roberto Cianni,
More informationHepatocellular carcinoma (HCC) is a highly prevalent
Dosimetry Based on 99m Tc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with 90 Y-Loaded Glass Microspheres: Preliminary
More informationSIRTEX Lunch Symposium, Cebu, 23 Nov Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong
SIRTEX Lunch Symposium, Cebu, 23 Nov 2013 Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong I will not talk on Mechanism of SIRT Data on efficacy of SIRT Epidemiology
More informationIn- and exclusion criteria
In- and exclusion criteria Kerstin Schütte Department of Gastroenterology, Hepatology and Infectious Diseases University of Magdeburg Overview: Study population Inclusion criteria I - General criteria
More informationTranscatheter hepatic arterial chemoembolization may be considered medically necessary to
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY Hepatocellular carcinoma Transcatheter hepatic arterial chemoembolization
More informationNews Release. Embargoed until 1:45 p.m. ET, Sunday, October 28, 2012
News Release Embargoed until 1:45 p.m. ET, Sunday, October 28, 2012 Contact: Michelle Kirkwood 703-286-1600 michellek@astro.org Concurrent use of sorafenib and stereotactic body radiotherapy for advanced
More informationRADIOEMBOLIZZAZIONE NEI TUMORI EPATICI: STATO DELL ARTE. clic per modificare lo stile del sottotitolo dello schem
XII Congresso Nazionale AIMN 2015 16-19 Aprile 2015 Rimini RADIOEMBOLIZZAZIONE NEI TUMORI EPATICI: STATO DELL ARTE clic per modificare lo stile del sottotitolo dello schem Marco Maccauro Nuclear Medicine
More informationsoramic newsletter no. 1 / 2015
Page 1 Message from the PIs Dear colleagues and friends; esteemed members of the SORAMIC study group, This newsletter is specifically dedicated to the prevention and treatment of radioembolization induced
More informationCOMPARING Y90 DEVICES
COMPARING Y90 DEVICES William S Rilling MD, FSIR Professor of Radiology and Surgery Director, Vascular and Interventional Radiology Medical College of Wisconsin DISCLOSURES Research support : Siemens,
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationSelective Internal Radiation Therapy. Jefferson R. Pagsisihan, MD, DPSNM The Medical City St. Luke s Medical Center
Selective Internal Radiation Therapy Jefferson R. Pagsisihan, MD, DPSNM The Medical City St. Luke s Medical Center S Selective Internal Radiation Therapy catheter-based liver directed modality for patients
More informationRADIATION SEGMENTECTOMY. Robert J Lewandowski, MD
RADIATION SEGMENTECTOMY Robert J Lewandowski, MD Robert Lewandowski, M.D. Consultant/Advisory Board: Cook Medical, LLC, Arsenal, BTG International, Boston Scientific Corp., ABK Reference Unlabeled/Unapproved
More informationHepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation
Original rticle Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation Giovanni attista Levi Sandri 1, Giuseppe Maria Ettorre 1, Marco Colasanti
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationSORAMIC: NM Procedures
: NM Procedures J. Ruf Klinik für Radiologie und Nuklearmedizin : NM Procedures Evaluation - 99m Tc MAA Scintigraphy Lung shunt assessment Treatment activity determination Therapy - 90 Y-SIR-Spheres Procedure
More informationProton Beam Therapy for Hepatocellular Carcinoma. Li Jiamin, MD Wanjie Proton Therapy Center
Proton Beam Therapy for Hepatocellular Carcinoma Li Jiamin, MD Wanjie Proton Therapy Center 1 1 Hepatocelluar carcinoma (HCC) is one of the most common cancers worldwide It is the eighth most common neoplasm
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationDescription. Section: Therapy Effective Date: July 15, 2014 Subsection: Therapy Original Policy Date: June 7, 2012 Subject: Page: 1 of 23
Last Review Status/Date: June 2014 Page: 1 of 23 Description Radioembolization (RE), referred to as selective internal radiation therapy or SIRT in older literature, is the intra-arterial delivery of small
More informationRadioembolization for the treatment of hepatocellular carcinoma
pissn 2287-2728 eissn 2287-285X Review https://doi.org/10.3350/cmh.2017.0004 Clinical and Molecular Hepatology 2017;23:109-114 Radioembolization for the treatment of hepatocellular carcinoma Hyo-Cheol
More informationtreatment options for primary liver malignancies and metastatic disease
State of the art treatment options for primary liver malignancies and metastatic disease Peter Huppert Prof. of Radiology and Neuroradiology Klinikum Darmstadt Certified Vascular and Oncologic Center Disclosure
More informationTranscatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies. Original Policy Date
MP 8.01.09 Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date
More informationFuture Needs for Standards in 90 Y Microsphere Therapy. CIRMS 2012 Reed Selwyn, PhD, DABR 24 October 2012
Future Needs for Standards in 90 Y Microsphere Therapy CIRMS 2012 Reed Selwyn, PhD, DABR 24 October 2012 Objectives I. General Description Microsphere Distribution Product Comparison II. Dosimetry Models
More informationImaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma
ORIGINAL CONTRIBUTION Imaging in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma Ahsun Riaz, MD Frank H. Miller, MD Laura M. Kulik,
More informationINCIDENTAL FINDING DURING CARDIOMYOPATHY WORKUP
Originally Posted: February 01, 2015 INCIDENTAL FINDING DURING CARDIOMYOPATHY WORKUP Resident(s): Mariya Gusman, M.D. Attending(s): Raul Palacios, M.D. Program/Dept(s): Brooke Army Medical Center DISCLAIMER
More informationRadioembolization of Colorectal Hepatic Metastases Using Yttrium-90 Microspheres
Radioembolization of Colorectal Hepatic Metastases Using Yttrium-90 Microspheres Mary F. Mulcahy, MD 1, Robert J. Lewandowski, MD 2, Saad M. Ibrahim, MD 2, Kent T. Sato, MD 2, Robert K. Ryu, MD 2, Bassel
More informationPortal Vein Invasion and the Role of Liver Directed Therapy. Matthew S Johnson MD FSIR Indiana University May 6, 2016
Portal Vein Invasion and the Role of Liver Directed Therapy Matthew S Johnson MD FSIR Indiana University May 6, 2016 Matthew Johnson, M.D., FSIR Stock: Endoshape Consultant/Advisory Board: Bayer, BTG,
More informationSIRT in Neuroendocrine Tumors
SIRT in Neuroendocrine Tumors Marnix G.E.H. Lam, MD PhD Professor of Nuclear Medicine AVL Amsterdam UMC Utrecht ENETS Center of Excellence, The Netherlands Disclosure of speaker s interests Consultant
More informationNonsurgical Treatment for Localized Hepatocellular Carcinoma
Curr Oncol Rep (2014) 16:373 DOI 10.1007/s11912-013-0373-x GASTROINTESTINAL CANCERS (B CZITO, SECTION EDITOR) Nonsurgical Treatment for Localized Hepatocellular Carcinoma Andrew S. Kennedy & Bruno Sangro
More informationResection leads to cure in selected patients with hepatocellular
Overview: Where Does Radiation Therapy Fit in the Spectrum of Liver Cancer Local-Regional Therapies? Laura A. Dawson, MD*, Experience with radiation therapy for the treatment of hepatocellular carcinoma
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More informationTransarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.2.473 Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions MINI-REVIEW Transarterial Therapies
More informationNIH Public Access Author Manuscript Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2013 July 01.
NIH Public Access Author Manuscript Published in final edited form as: Int J Radiat Oncol Biol Phys. 2012 July 1; 83(3): 887 894. doi:10.1016/j.ijrobp.2011.07.041. Radioembolization for Neuroendocrine
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationCorrespondence should be addressed to O. Audrain;
International Hepatology Volume 2013, Article ID 827649, 8 pages http://dx.doi.org/10.1155/2013/827649 Clinical Study Lobar Hepatocellular Carcinoma with Ipsilateral Portal Vein Tumor Thrombosis Treated
More informationCorrespondence should be addressed to Constantinos T. Sofocleous;
Case Reports in Hepatology, Article ID 921406, 4 pages http://dx.doi.org/10.1155/2014/921406 Case Report Safe and Successful Yttrium-90 Resin Microsphere Radioembolization in a Heavily Pretreated Patient
More informationPresentation by Dr. Thomas Yau on behalf of his co-authors
4078 First presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago, Illinois, USA, June 3-7, 2016. Reused with permission from the American Society of Clinical Oncology
More informationRadioembolization (RE) is a form of brachytherapy. Prognostic Factors and Prevention of Radioembolization-Induced Liver Disease
Prognostic Factors and Prevention of Radioembolization-Induced Liver Disease Belen Gil-Alzugaray, 1,2 Ana Chopitea, 2,3 Mercedes I~narrairaegui, 1,2,4 Jose I. Bilbao, 2,5 Macarena Rodriguez-Fraile, 2,6
More informationMultiple Primary Quiz
Multiple Primary Quiz Case 1 A 72 year old man was found to have a 12 mm solid lesion in the pancreatic tail by computed tomography carried out during a routine follow up study of this patient with adult
More informationPEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good
Reviewer s code: 03656588 Reviewer s country: China Date reviewed: 2017-06-08 [ ] Grade A: Excellent [ Y] Accept [ ] Grade B: Very good [ ] High priority for [ Y] Grade C: Good language [ ] Major revision
More informationThe Role of Tumor Vascularity in Predicting Survival after Yttrium-90 Radioembolization for Liver Metastases
The Role of Tumor Vascularity in Predicting Survival after Yttrium-90 Radioembolization for Liver Metastases Kent T. Sato, MD, Reed A. Omary, MD, Christopher Takehana, MD, Saad Ibrahim, MD, Robert J. Lewandowski,
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationHepatocellular carcinoma (HCC) is the sixth most common
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2013;11:604 611 Chemoembolization and Radioembolization for Hepatocellular Carcinoma RIAD SALEM and ROBERT J. LEWANDOWSKI Section of Interventional Radiology, Division
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationClinical trials evaluating the use of Yttrium-90. Copyright HMP Communications
Optimizing Reimbursement for Radioembolization: The Importance of Adequate Documentation Rishi Chopra, MS 1 ; Jason C. Hoffmann, MD 1 ; Amanjit S. Baadh, MD 2 From 1 Winthrop University Hospital, Department
More informationThe Role of Interventional Radiology (Locoregional
The Role of Interventional Radiology (Locoregional therapies) in HCC Richard Owen MB, MRCP, FRCR Interventional Radiology, Associate Professor University of Alberta Aldo Montana-Loza MD, FRCPC Hepatology
More informationY-Microspheres Radioembolization for Selective Internal Radiation Therapy of Primary and Metastatic Cancer in the Liver
90 Y-Microspheres Radioembolization for Selective Internal Radiation Therapy of Primary and Metastatic Cancer in the Liver Pr Francesco Giammarile CHLS Lyon Faculté de Lyon Sud «Aut tace aut loquere meliora
More informationRegional Therapy for Metastatic Neuroendocrine Tumors. Janette Durham, MD Professor of Radiology University of Colorado School of Medicine
Regional Therapy for Metastatic Neuroendocrine Tumors Janette Durham, MD Professor of Radiology University of Colorado School of Medicine Introduce regional therapy for mnet Arterial therapies Injection
More information